Drug survival of the infliximab biosimilar (CT-P13) in paediatric patients with non-infectious uveitis - Concepedia

Concepedia

Publication | Closed Access

Drug survival of the infliximab biosimilar (CT-P13) in paediatric patients with non-infectious uveitis

10

Citations

0

References

2021

Year

Betül Sözeri, Esra Kardeş, Enes Salı, Deniz Çakır, Ferhat Demir

Clinical and Experimental Rheumatology

Abstract

To our knowledge, this is the first study to assess the impact of CT-P13 treatment adherence on disease activity in children with NIU. The IFX biosimilar CT-P13 is remarkably safe and effective for the long-term treatment of paediatric NIU.